Granulocyte-targeted therapies for airway diseases

Tavares, L. P., Peh, H. Y., Tan, W. S. D., Pahima, H., Maffia, P. , Tiligada, E. and Levi-Schaffer, F. (2020) Granulocyte-targeted therapies for airway diseases. Pharmacological Research, 157, 104881. (doi: 10.1016/j.phrs.2020.104881)

[img] Text
214931.pdf - Accepted Version
Available under License Creative Commons Attribution Non-commercial No Derivatives.



The average respiration rate for an adult is 12-20 breaths per minute, which constantly exposes the lungs to allergens and harmful particles. As a result, respiratory diseases, which includes asthma, chronic obstructive pulmonary disease (COPD) and acute lower respiratory tract infections (LTRI), are a major cause of death worldwide. Although asthma, COPD and LTRI are distinctly different diseases with separate mechanisms of disease progression, they do share a common feature – airway inflammation with intense recruitment and activation of granulocytes and mast cells. Neutrophils, eosinophils, basophils, and mast cells are crucial players in host defense against pathogens and maintenance of lung homeostasis. Upon contact with harmful particles, part of the pulmonary defense mechanism is to recruit these cells into the airways. Despite their protective nature, overactivation or accumulation of granulocytes and mast cells in the lungs results in unwanted chronic airway inflammation and damage. As such, understanding the bright and the dark side of these leukocytes in lung physiology paves the way for the development of therapies targeting this important mechanism of disease. Here we discuss the role of granulocytes in respiratory diseases and summarize therapeutic strategies focused on granulocyte recruitment and activation in the lungs.

Item Type:Articles
Additional Information:Francesca Levi-Schaffer's research is funded partly by the Israel Science Foundation, Rosetrees Trust (United Kingdom), Aimwell Charitable Trust (United Kingdom), the United States–Israel Binational Science Foundation (BSF), and the Israel Ministry of Science and Technology. Hong Yong Peh is a recipient of National University of Singapore Overseas Postdoctoral Fellowship and co-funded by Harvard Medical School and Brigham and Women's Hospital.
Glasgow Author(s) Enlighten ID:Maffia, Professor Pasquale
Authors: Tavares, L. P., Peh, H. Y., Tan, W. S. D., Pahima, H., Maffia, P., Tiligada, E., and Levi-Schaffer, F.
College/School:College of Medical Veterinary and Life Sciences > Institute of Cardiovascular and Medical Sciences
College of Medical Veterinary and Life Sciences > Institute of Infection Immunity and Inflammation
Journal Name:Pharmacological Research
ISSN (Online):1096-1186
Published Online:04 May 2020
Copyright Holders:Copyright © 2020 Elsevier Ltd.
First Published:First published in Pharmacological Research 157:104881
Publisher Policy:Reproduced in accordance with the copyright policy of the publisher

University Staff: Request a correction | Enlighten Editors: Update this record